Navigation Links
ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience™ Line of Dietary Supplements

IRVINE, Calif., May 17, 2012 /PRNewswire/ -- ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today that customer demand and unit sales of its recently launched BluScience™ line of dietary supplements have exceeded the Company's initial forecast and expectations during the first quarter ended March 31, 2012.



The nationwide launch of BluScience™ in retail outlets began in earnest in early 2012 whereby BluScience™ became available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S.

In the first quarter of 2012, the initial launch achieved sales of more than 125,000 units of BluScience™, more than 50 percent higher than the Company's initial forecast. Sales deductions for promotions and discounts related to the sale of BluScience™ product totaled $2,249,168 in the first quarter, resulting in net sales of BluScience™ products of $69,742. Higher than expected consumer demand for the BluScience™ line resulted in higher than expected promotional expenses.

As planned, promotional activities, discounted pricing and media programs were used to generate interest, and played a key role in the launch and initial consumer awareness of the product line.

Frank Jaksch, Co-Founder and CSO of ChromaDex® commented, "ChromaDex® made a strategic decision to significantly invest in our patented and proprietary pTeroPure® by creating and launching the BluScience™ product line as well as financing the first human clinical study of pTeroPure®. The results will provide an important independent clinical assessment of what we believe is an enormous opportunity with this product."

ChromaDex® announced in December 2011 the successful completion of enrollment in the first human clinical study of pTeroPure®. The randomized, double-blind placebo-controlled study evaluated pTeroPure® effects on blood pressure, total triglycerides, cholesterol, as well as improve markers for oxidative stress in patients with dyslipidemia-meeting inclusion criteria. Investigators are also evaluating the safety of pTeroPure® in these patients and other ends points, such as weight loss.

The BluScience™ line is currently comprised of:

  • EternalBlu - supports cellular health and has anti-aging properties
  • HeartBlu - helps maintain healthy cholesterol levels and supports cardiovascular health
  • MemoryBlu - supports concentration, memory and cognitive function
  • TrimBlu - helps control appetite and supports healthy metabolism
  • Blu2Go - provides a sustained energy boost and supports focus & mental clarity

The novel ingredient in BlūScience™ is ChromaDex®'s proprietary, patented pterostilbene, branded as pTeroPure®, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.

pTeroPure® is a proprietary, nature-identical formulation of the compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (phytochemicals with antioxidant activities that help fight free radicals), allowing more time for its antioxidant activities to act. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience™ capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.

About ChromaDex®:

ChromaDex®, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights. The company recently launched its BluScience™ line of dietary supplements, now available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in North America. BluScience™ is also available at a prominent online retailer, as well as a national health and nutrition products retailer. Capitalizing on the diverse potential applications of the product, ChromaDex® is also investigating pTeroPure® for the skincare and pharmaceutical markets, among others. pTeroPure® is currently being studied in a human clinical trial at the University of Mississippi. For more information about pTeroPure® visit or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex® Investor Contact: 
The Del Mar Consulting Group, Inc.
Robert B. Prag, President


Alex Partners, LLC
Scott Wilfong, President

ChromaDex® / BluScience Contact:
Laura Carney, Executive Assistant


SOURCE ChromaDex
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OPKO Health, Inc. Invests in ChromaDex® Corp.
2. ChromaDex® Announces Letter of Intent Signed with Glanbia Nutritionals for Partnership on pTeroPure®
3. ChromaDex®s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers
4. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
5. Approximately One-Third of MS Patients Experiencing Relapses Do Not Adequately Respond to Traditional Corticosteroid Therapy, According to New Data Presented at the 5th Joint Congress of the European and Americas Committees for Treatment and Researc
6. Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
7. China Biologic Products Reports Higher Results for the First Quarter 2012
8. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
9. Published Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT
10. Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population
11. Higher Mobility Announces Residential Lift Briefing Sessions for Physical Therapists, Caseworkers, Social Workers, Skilled Nurses
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve ... the bather’s style and personality. From basic styles for the purist looking for ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
Breaking Medicine News(10 mins):